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Abstract
Immunophenotyping is an essential part of the modern diagnostic workup of acute leu‐
kemias and thus for an appropriate treatment of these complex and heterogeneous dis‐
eases. It provides a lot of useful information in this setting that transfers directly from
laboratory to clinical management of patients. Lineage definition is the first goal leading
to proper initial therapy. Some phenotypic patterns define specific subsets correlating
with poor (mixed phenotype, dendritic cell neoplasm) or favorable (cortical T-lympho‐
blastic leukemia) outcome, thus guiding the application of treatment modalities. An ad‐
vanced analysis of phenotypic data can address specific issues, such as the still debated
role of multilineage dysplasia. The quality of response to chemotherapy is monitored by
the detection of minimal residual disease and peripheral blast clearance during chemo‐
therapy delivering. That allows a sharp discrimination of prognosis and again can drive
the intensity of therapies proportionally to the disease chemosensitivity.
Keywords: Acute myeloid leukemia, acute lymphoblastic leukemia, diagnosis, prognosis,
chemosensitivity, minimal residual disease
1. Introduction
1.1. Definition and clinical picture
Acute leukemias (AL) are hematological neoplasms featured by altered proliferation and/or
differentiation of hematopoietic progenitors, leading to accumulation of immature cells in
bone marrow (BM) and peripheral blood (PB). The clinical consequences are thus due to BM
failure and infiltration of extra-hematological sites by leukemic cells, possibly causing organ
function impairment. BM failure and related reduction in peripheral mature elements are
responsible for the majority of clinical signs and symptoms at disease onset, that is, fatigue,
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
skin pallor, tachycardia (due to anemia), infections (due to neutropenia and/or T-cell deficien‐
cy), and hemorrhage (due to thrombocytopenia and/or coagulopathy). The clinical spectrum
can be very wide, ranging from complete lack of manifestations to life-threatening ones. As
such, a correct diagnosis is the first step for the right management of patients affected by AL.
1.2. Principles of treatment
Overall, treatment of AL goes through two main phases: induction and consolidation. The
primary target of induction phase is the achievement of a complete remission (CR), which is
defined by the decrease of immature cells below 5% of global BM cells at morphologic
evaluation [1]. The benchmark of induction is chemotherapy, with different drugs, dosages,
and schedules, depending on lineage definition and further on subclassification within
different lineages. Some specific subsets [i.e., acute promyelocytic leukemia, Philadelphia-
positive acute lymphoblastic leukemia (ALL)] benefit from the application of therapies
targeted toward their unique underlying molecular pathways of leukemogenesis. Once more,
the delivery of an appropriate treatment from the outset strictly depends upon AL’s precise
diagnostic definition. CR attainment is a prerequisite for long-term survival; once obtained,
the consolidation phase deals with lowering the risk of relapse. Consolidation strategies
include allogeneic hematopoietic stem cell transplantation (HSCT), providing the highest
impact on relapse risk, chemotherapy, or autologous transplant. The use of allogeneic HSCT
is generally reserved to patients with high relapse risk or with refractory disease, given the
relevant treatment-related toxicity and mortality. The appraisal of prognosis at disease onset
and during treatment phases is a dynamic and challenging process, with many potential
predictors in turn characterized by different effectiveness in different contexts. Again, this
process is the driver of important clinical decisions involving the application of highly toxic
therapies.
1.3. Role of immunophenotype
Immunophenotyping is an essential part of the modern diagnostic workup and prognostic
stratification of AL and thus for an appropriate treatment of these complex and heterogene‐
ous diseases. It provides a lot of useful information in this setting that transfers directly from
laboratory to clinical management of patients.
2. Diagnosis
According to the World Health Organization (WHO), ALs are defined as hematological
neoplasms featured by the presence of 20% or more immature cells (blasts) with respect to PB
or BM total cells [2, 3]. This benchmark threshold refers to morphology, which allows to
recognize blasts by specific immature properties of nucleus and cytoplasm. Similarly,
immunophenotyping permits to identify immature cells based on some immunological
characteristics and, specifically, a dim expression of CD45 with low/intermediate side scatter
signal [4]. Once identified, blasts are analyzed as regards the expression of a group of core
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antigens. The phenotypic profile of blasts is thus related to normal hematopoietic counter‐
part, to define main lineage of differentiation and subclassification.
2.1. AL lineage definition
The first and main purpose of AL immunophenotyping is lineage definition of blasts, as
myeloid or lymphoid, and in the latter case as B or T lymphoid. Lineage definition is based on
similarities in antigenic expression patterns to normal myeloid, B-lymphoid progenitors, or T-
lymphoid progenitors. With this respect, some “key” antigens have been defined for each
lineage based on early and exclusive expression within them. However, it was immediately
evident that in some AL forms, there was no clear-cut distinction and cross-lineage expres‐
sion was quite frequent. As such, the first systematic attempt to regulate these findings was
based on the concept that different antigens had a different weight for lineage attribution and
was done by European Group for Immunological Classification of Leukemia (EGIL) [5] (Table
1). Although rigid by definition, as any such classification, it had the fundamental merit of
creating a common reference for AL diagnosis. Recently many efforts have been tried to
ameliorate and fine-tune the basic concept of EGIL classification. On the one side, the core
group of lineage antigens has remained substantially the same: the interpretation of their
pattern for lineage attribution has been updated by the WHO 2008 Classification [6]. On the
other side, main efforts have been pursued to overcome the mere application of thresholds of
antigen positivity, based on scarce biologic plausibility, and to attain a higher level of
standardization. On this regard, the EuroFlow group has obtained amazing results toward
sample handling, optimization on combinations of monoclonal antibodies, and even data
analysis, possibly heading to go beyond dependence on operator [7].
Score Myeloid B lymphoid T lymphoid
2 cyMPO CD22, CD79a, cyIgM cyCD3, TCR
1 CD13, CD33, CD117, CD65 CD19, CD10, CD20 CD2, CD5, CD8, CD10
0.5 CD14, CD15, CD64 CD24, TdT TdT, CD7, CD1a
Abbreviations: MPO, myeloperoxidase; TdT, terminal deoxynucleotidyl transferase; cy, cytoplasmic; TCR, T-cell receptor.
More than 2 points are required to assign a lineage.
Table 1. Classification of European Group for Immunological Classification of Acute Leukemias
2.2. Diagnosis in challenging contexts
For an immediate diagnostic assessment, in the majority of cases, morphology is already able
to assign myeloid lineage mainly by revealing granules, Auer bodies, or monocytic features.
However, in several circumstances, immunophenotyping is absolutely essential for diagnos‐
tic workup:
• Morphologically undifferentiated blasts: when clear myeloid features are absent in PB- or
BM-stained slides, immunophenotyping is the cornerstone of AL diagnosis. That pro‐
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vides the basis for definition of myeloid or lymphoid leukemia, a definition leading to
completely different treatment strategies. In turn, within lymphoid lineages, phenotypic
pattern is the basis for subclassification, according to the expression of selected key antigens
in parallel with the maturation process in normal lymphopoiesis (Figure 1).
• Atypical presentation: ALs sometimes have atypical behavior, making hard to get a
diagnosis and thus adequate therapy. These relatively rare circumstances are as follows:
cases with low peripheral blast count and punctio sicca at BM aspiration; aplastic onset of T-
lymphoblastic leukemia; BM necrosis reported to be associated with ALL or NPM1-mutated
acute myeloid leukemia (AML) [8].
• Neoplasm of precursors of plasmacytoid dendritic cells: it is a novel subset in the WHO
classification of myeloid neoplasms, with heterogeneous clinical presentation and varia‐
ble extra-hematological infiltration. The normal counterpart of this tumor resides in the
plasmacytoid dendritic cell lineage and as such its diagnosis depends on revealing a
dendritic cell–related phenotype [9, 10]. The typical phenotypic profile consists of positivi‐
ty for CD4, CD56, and CD123, together with intense expression of HLA-DR and negativi‐
ty for main lineage antigens. In this setting, the phenotype provides an important piece of
clinical information since this disease has a dismal outcome with chemotherapy consolida‐
tion and allogeneic transplantation seems to provide better chances of cure [11].
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Figure 1. Subclassification of acute lymphoblastic leukemia in parallel to normal lymphopoiesis. Acute lympho‐
blastic leukemia of B lineage (panel A) and of lineage T (panel B) is classified according to phenotypic profile of blasts
and its similarity to the stages of physiological lymphopoiesis.
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2.3. Immunotherapy of AL
The application of immunotherapy is an emerging treatment approach in the field of AL. The
basic concept is the killing of leukemic cells by direct attack to molecules on the cell surface.
B-lineage antigens, CD19 and CD22, are effectively targeted by rituximab and inotuzumab,
respectively, in B-ALL. Gemtuzumab ozogamicin is directed to pan-myeloid antigen CD33
and it is used in AML. More recently, immunological therapies based on the activation of T
lymphocytes directly against blasts have been developed in B-ALL. This approach relies on
bispecific T-cell engager antibodies, such as blinatumomab [12], or on autologous T lympho‐
cytes engineered with chimeric activating receptors (CAR) [13] and represents one of the most
promising strategies in the therapy of this disease. It is obvious that the application of
immunotherapy relies on revealing the expression of the target antigens on the membrane of
pathologic cells and thus on proper immunophenotyping.
3. Correlation phenotype–genotype
Karyotype and molecular genetics still represent the cornerstone of prognostic stratification
of patients affected by AL. This information commonly drives the application of treatment. In
AL bearing recurrent cytogenetic abnormalities, leukemic cells often display shared antigen‐
ic patterns usually able to predict the underlying genotype. Generally, this association is strong
when few and relevant genetic events are responsible for leukemogenesis [i.e., CBF-AML,
t(15;17), Philadelphia chromosome], whereas it is weaker with higher genetic heterogeneity
(i.e., normal/intermediate karyotype with NPM1, FLT3, CEBPA, DNMT3A, IDH1-2 gene
mutations). The definition of such “predictive” profiles is based on entire phenotypic patterns
of blasts rather than on single antigen expression [14].
t(8;21): AML with t(8;21) is typically featured by maturation asynchrony, that is, high
expression of CD34 together with mature antigens as CD15 and myeloperoxidase. Most cases
display a cross-lineage co-expression of “dim” CD19. TdT and CD56 are common aberran‐
cies on blasts. Maturing neutrophil compartment often shows phenotypic abnormalities
(lack of CD10, expression of CD56) as well, due to its belonging to leukemic clone.
inv(16): often associated with eosinophilia, blasts of this AML subset show co-expression of
immature antigens concomitantly to markers of granulocyte (CD15, CD65) or monocyte
differentiation (CD14, CD4). In approximately half of cases, a cross-lineage expression of CD2
is observed.
NPM1: AML with mutations in the NPM1 gene usually shows monocytic differentiation. When
detectable, myeloid blasts are often featured by negativity or dim expression for CD34 [15].
Typically, monocytic cells display immature phenotypic profile.
t(15;17): acute promyelocytic leukemia has two main characteristics: life-threatening coagul‐
opathy and sensitivity to a differentiating treatment consisting of all-trans retinoic acid. Both
of them prompt the urgency of a correct suspect and consequent diagnosis. In this light, the
interpretation of the phenotypic profile of blasts is crucial. Leukemic promyelocytes typical‐
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ly have the phenotype of their normal counterpart (i.e., high side scatter signal with intense
expression of CD33 and CD64, heterogeneous expression of CD13, negativity for HLA-DR)
but with dim/negative CD15 [16]. Cross-lineage expression of CD56 can occur, with debata‐
ble prognostic meaning. A population of basophils with extremely high side scatter signal
(SSC) can also be revealed.
t(9;22): this chromosomal aberration causes a chimeric fusion gene called BCR/ABL, a crucial
event in leukemogenesis. Within ALs, the majority of cases bearing this translocation are B-
precursor ALL and, frequently, are featured by CD10 expression. Moreover, most cases display
several aberrant features. Among them, the expression of myeloid antigens (CD13 and/or
CD33) is frequent as well as the expression of CD25 (interleukin-2 receptor alpha chain). Rather
than a single aberration, the whole phenotype of blasts can reliably predict an underlying
t(9;22), as reported by Tabernero et al. [17].
In the field of genotype prediction, a novel application of flow cytometry (FC) based upon an
immunobead assay has been developed. This kind of test is able to detect the presence of
chimeric proteins coded by relative fusion genes such as PML/RARalfa and BCR/ABL and,
obviously, has the advantage to provide earlier results compared to PCR [18, 19].
Due to the capability to provide early results, immunophenotype is extremely useful to guide
the analysis of karyotype and molecular genetics, aiding the application of the FISH method,
for example. In this context, immunophenotyping can have a crucial role when karyotypic
analysis results in lack of growth. The phenotypic profile can reliably channel genetic analyses
toward most probable mutations, thus tuning an otherwise undefined prognostic assessment.
4. Prognostic value at baseline
As described above, immunophenotyping has mainly a diagnostic role in AL field. At any rate,
there are some specific, less common subsets where FC assumes a significant prognostic
weight, upon which clinicians can apply a proportional treatment strategy. These subsets are
as follows:
4.1. Mixed Phenotype (MP) AL
The concomitance of expression of antigens belonging to different lineages has demonstrat‐
ed to correlate with dismal prognosis. Consistently, the WHO classification considers these
cases as a separate entity. The diagnostic criteria in the WHO 2001 classification adopted those
previously defined by EGIL (see Table 1): a score >2 points for two or more lineages defined
biphenotypic AL [5]. The WHO 2008 classification has established new criteria for the
diagnosis of this subset, also renamed as MP-AL. Highly lineage-specific antigens are required
for T- (cyCD3) and myeloid (myeloperoxidase and/or evident monocytic differentiation)
lineage attribution. For B-lineage, one or three B-lineage markers have to be expressed
depending upon intense or weak expression for CD19 [6]. MP-AL is usually associated with
unfavorable karyotype, MLL/11q23 rearrangements, or BCR/ABL gene fusion. Patients
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affected by MP-AL are characterized by unfavorable prognosis and should be considered for
allogeneic HSCT once in CR [20].
4.2. Cortical T (EGIL T-III) acute lymphoblastic leukemia
This subset is defined by the expression of CD1a (see Figure 1). In a large multicenter
prospective trial by UKALL and ECOG, a lower relapse risk and a longer overall survival were
observed for this category of patients [21]. This immunological feature is often used for
prognostic stratification of T-ALL.
4.3. Early T (ETP) ALL
A specific immature T phenotype, featured by absence of CD1a and CD8, weak CD5, and
expression of one or more myeloid or stem cell-related antigens, has been associated with low
response rate to chemotherapy and dismal prognosis [22]. However, the prognostic analyses
within more modern clinical trials have shown survival similar to non-ETP ALL and the
prognostic meaning of this subgroup is still under debate [23].
5. Advanced phenotypic analysis: assessment of multilineage dysplasia
Several papers have addressed the role of multilineage dysplasia (MLD) in AML leading to
conflicting results, possibly because of technical and biological reasons [24, 25]. Technical
reasons deal with morphological assessment of residual hematopoiesis at AML diagnosis, that
is the standard criteria for defining MLD. Morphology is operator dependent; its specific
application is even more complicated in this setting because residual nonblast cells are very
few at diagnosis. Biologically, the MLD-related unfavorable prognosis would rely on clonal
involvement at stem cell level or on pre-existing clonal hematopoiesis, conferring bad
prognosis to AML. However, MLD might merely result from pathologic differentiation/
maturation of the leukemic clone. We thus estimated MLD by FC, which is emerging as a useful
method to study dysplasia, mainly by investigating the expression of key antigens through‐
out myeloid maturation. Our rationale was that an FC-based evaluation of dysplasia could get
further insight into MLD actual significance. The application of FC to study BM maturing cell
compartments in AML can provide many advantages compared to morphology: i) the amount
of studied cells is much larger; ii) phenotypic parameters can be quantified and referred to
control groups and, as such, reliably standardized; iii) phenotypic scores can be calculated,
thus estimating accurately the extent of dysplasia; iv) there exists a capability to reveal
dysplasia even in the absence of atypical morphology in MDS, as shown in a recent report [26].
Technically, the appraisal of MLD was based on a group of control BMs used to set normal
phenotypic profile of maturing (i.e., neutrophil and erythroid) compartments; phenotypic
abnormalities in AML were thus highlighted by reference to controls and the degree of
dysplasia was appraised by a score proportional to deviation from normal phenotypic profile.
We focused our analysis on NPM1-mutated AML, for which a major controversy in the WHO
classification exists. In fact, it is still under debate how to classify cases presenting with MLD
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and a concomitant NPM1 mutation. This issue has relevant implications since NPM1-mutat‐
ed status correlates with a relatively good prognosis (especially when FLT3-wt) [27].
Our study provided evidence that MLD, as assessed by immunophenotype, has no impact on
clinical characteristics and outcome in NPM1+ AML. By investigating NPM1 status on
separated cell compartments, we have established a correlation between MLD and belong‐
ing to AML clone [28] (Figure 2). Together with previous reports [29, 30], our findings further
support MLD to be part of the spectrum of NPM1+ AML, without any relevant influence on
major disease features and outcome. As such, these data strongly suggest the classification and
the prognostic stratification of this category of patients should not be based upon MLD.
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Figure 2. NPM1 mutational analysis on sorted cell fractions. Cell compartments are shown at the top; as concerns
neutrophil compartment (left), the results of clustering analysis are depicted, together with phenotypic parameters and
compartment’s phenotypic score (IPS), appraising the extent of dysplasia. In the corresponding plots, the cell popula‐
tion is highlighted by color: blue for neutrophil cells, red for blasts, orange for T lymphocytes. The relative data from
NPM1 mutational analysis are reported below. (A) Patient #1: neutrophil compartment showed several phenotypic
abnormalities (as represented by clustering analysis and IPS = 6.0) and harbored NPM1 mutation; sorted blasts and T
lymphocytes were NPM1-mutated and wild-type, respectively. (B) Patient #2: neutrophil compartment showed a pre‐
served phenotypic profile (IPS = 0) and a NPM1 wild-type status. Sorted blasts and T lymphocytes were NPM1-mutat‐
ed and wild-type, respectively. Clustering analysis was performed by R software. Dot plots were created by Infinicyt
software. NPM1 mutational analysis: in order to discriminate NPM1 PCR products, we used 5’- end HEX dye-labeled
reverse primer (M-Medical). The amplified products were separated with a capillary electrophoresis-based system us‐
ing ABI PRISM 310 genetic analyzer (Applied Biosystems). The labeled fragment size corresponding to NPM1 wild-
type gene was 347 bp. All NPM1-mutated samples were heterozygous, showing a double peak at positions 347 (wt)
and 351 (mut).
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6. Chemosensitivity assessment: minimal residual disease and peripheral
blast clearance
Identification of AL patients who would have high likelihood to respond to standard induc‐
tion therapy and those with low probability to do well and those who are candidates for more
aggressive treatment is of major clinical importance. Most clinical and biological prognostic
factors are based on characteristics of the patient and the disease at diagnosis and are surrogate
for disease’s chemosensitivity [31, 32]. In AML, the European Leukemia Net (ELN) stratifica‐
tion system is one of the most adopted systems and is based on cytogenetic/molecular
abnormalities [31]. In fact, it allows to define patients’ subgroups featured by high likeli‐
hood to achieve CR and long survival (ELN-favorable) and at the opposite a category with
scarce response to chemotherapy and dismal prognosis (ELN-adverse). However, in the
absence of genetic determinants, the ELN system merges patients with heterogeneous
diseases (intermediate-1 and 2), where its clinical utility has major concerns. The same issue
regards the field of ALL. The actual BM response to chemotherapy allows to refine the
pretreatment risk stratification as it expresses the actual chemosensitivity resulting from killing
leukemic cells.
6.1. Minimal Residual Disease (MRD)
Within responding patients, the detection of MRD beyond morphologic definition of CR is
emerging as an accurate tool to refine risk category assignment, as initially established upon
cytogenetic/genetic findings. FC allows to study MRD in the vast majority of patients (about
85% in AML, 90–95% in ALL), which is an advantage compared to molecular techniques.
The core concept of MRD by FC is the detection of one or more leukemia-associated aber‐
rant immunophenotypes (LAIP), as phenotypic profiles that are absent or very rare on normal
cells [33–35]. The sensitivity of MRD by FC ranges between 10−3 and 10−4. MRD is usually
estimated as the percentage of LAIP+ cells on global BM cells at certain time points. An
alternative approach exploits logarithmic decrease of LAIP+ cells from diagnosis to BM
assessment [36]. Conventionally, MRD is evaluated upon full recovery of PB counts after one
and/or two chemotherapy cycles [33, 37]. An earlier BM morphologic and FC evaluation (7
days after completing induction) has been shown to correlate with CR achievement and
survival [36]. Also at later time points in the treatment plan, for instance, before allogeneic
HSCT, MRD confirms its prognostic weight [38].
In ALL, and especially in childhood, MRD by immunophenotype has been embedded within
main clinical trials and is used to drive treatment strategy [39]. In AML, in spite of a clear
prognostic meaning, MRD by FC has not found a defined place in clinical practice yet. The
only published trial basing a clinical decision on MRD regarded the field of childhood AML
[40]. Main reasons of this discrepancy between ALL and AML reside probably in a higher
phenotypic heterogeneity of both normal and leukemic myeloid hematopoiesis compared to
lymphopoiesis and ALL. Strictly linked to this subject, a substantial lack of standardization in
method and data interpretation is still a major concern of FC in MRD setting, compared to
molecular techniques.
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6.2. Peripheral Blast Clearance (PBC)
Early response to treatment, and specifically to steroids, has been established as an impor‐
tant prognostic factor in ALL [41]. In modern therapy, this parameter is appraised by clini‐
cians, but it is not generally considered per se as a driver of treatment modalities.
In AML, risk-oriented treatment exclusively concerns post-induction phase. As said before,
the disease’s characterization at diagnosis and the quality of response to therapy (estimated
by MRD) are integrated to define a prognostic assessment that guides the consolidation phase.
In fact, induction is delivered irrespectively of patient or AML features.
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Figure 3. Relationship between peripheral blast clearance (PBC) during induction therapy and bone marrow re‐
sponse in AML. (A) PBC promptly resolves responders (CR) from nonresponder (NCR) patients. Log reduction is the
ratio between baseline and daily absolute LAIP+ blast count converted to a logarithmic scale. The ranges of log reduc‐
tion show minimal overlap between the two groups. Horizontal bars are medians, boxes are 25th percentiles, and
whiskers are 75th percentiles. Dots are outliers. (B) Bone marrow blast clearance correlates with PBC. In this graph, the
log decrease in bone marrow LAIP+ blasts (assessed by flow cytometry on day 14) is in linear relationship to log reduc‐
tion of LAIP-positive blasts from peripheral blood at day 5 of induction treatment. In fact, a linear statistically signifi‐
cant correlation is found as from day 2.
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To assess AML chemosensitivity in a relevant clinical time, we have evaluated the kinetics of
leukemic cell reduction from PB during induction. To do this, we have quantified LAIP+ cell
population on PB immediately before and daily during induction course. The ratio between
absolute LAIP+ baseline and daily values converted to a logarithmic scale was defined as
peripheral blast clearance (PBC).
We carried out a daily quantitative assessment of peripheral blasts during conventional “3+7”
course in a cohort of 61 patients. We documented that PBC strictly correlated with the decrease
of the overall leukemic burden in the patient. Specifically, we observed that PBC discriminat‐
ed between responsive and refractory patients since day 2 of therapy [42, 43] (Figure 3). Being
a very early and powerful predictor of CR achievement and outcome, PBC could allow to
modulate the intensity of treatment since induction phase, providing an in vivo chemosensi‐
tivity assay in AML.
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